Vascular Mimicry May be Prognostic Factor for Survival in RCC

Share this content:
Vascular mimicry may be a prognostic factor for recurrence-free survival in clear-cell renal cell carcinoma after radical nephrectomy.
Vascular mimicry may be a prognostic factor for recurrence-free survival in clear-cell renal cell carcinoma after radical nephrectomy.

Vascular mimicry may be a prognostic factor for recurrence-free survival (RFS) in patients with clear-cell renal cell carcinoma (ccRCC) after radical nephrectomy, according to a Chinese population study published in The Journal of Urology.1

Researchers led by Lin Zhou, PhD, of Fudan University in Shanghai conducted a retrospective cohort study of 387 patients with ccRCC who had undergone radical nephrectomy at the university between 2008 and 2009. They recorded pathologic features, baseline patient characteristics, and follow-up data for all patients.

Vascular mimicry in ccRCC tissue was identified through CD31-PAS double staining, and univariate and multivariable Cox regression models were used to analyze the impact of prognostic factors on RFS.

They found that positive vascular mimicry staining occurred in 6.5% of all observed ccRCC cases, and it was associated with an increased risk of recurrence. In addition, vascular mimicry was identified as an independent prognostic factor.

RELATED: Metabologram May Help Combat Kidney Cancer in a Novel Way

“Further external validation and functional analysis should be pursued to assess its potential prognostic and therapeutic values for ccRCC patients,” the authors concluded.

Reference

  1. Zhou L, Chang Y, Xu L, et al. The presence of vascular mimicry predicts high recurrence risk of clear-cell renal cell carcinoma after radical nephrectomy [published online ahead of print March 10, 2016]. J Urol. doi: 10.1016/j.juro.2016.02.2971.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters